Patent Application
20090098222
The present invention relates to an agent for promoting calcium absorption.
A level of calcium within the living body is constantly maintained by balancing between absorption and excretion from the gastrointestinal tract, and renal tubular reabsorption and excretion, respectively. Consequently, calcium deficiency is one of the symptoms of chronic renal failure. Also, calcium deficiency is often found since it is not easy to find various foods containing a lot of calcium, and an efficiency of the absorption is not sufficient in many cases. Calcium deficiency is responsible for brittle bones and may cause osteoporosis and osteomalacia, and thus it is hoped to establish a method for improving an efficiency of the calcium absorption from the small intestine and/or bone absorption of calcium.
As maintaining a balanced blood calcium is essential for good cardiac function, calcium deficiency has also been linked to cardiovascular disorders such as atherosclerosis, coronary artery disease, ischemic heart disease, hyperlipidemia and hypertension. Calcium has also been found to lower cholesterol levels.
Other conditions which may benefit from improved calcium absorption are malaria, ulcerative colitis, gingivitis or dental plaque, and learning defects such as Alzheimer's or senile dementia.
GA is a gummy exudation obtained from the stems and/or branch or Acacia senegal (Leguminosae) or other Acacia species (Leguminosae). The major component of GA is arabic acid (79 to 81%), which exists as Ca, Mg and/or K salts. Acid hydrolysis of GA yields L-arabinose, D-galactose, L-rhamnose, and D-glucuronic acid. In addition, traces of hydrolase and oxidase are present, together with a little amount of mineral and proteins in GA.
From the era of ancient Egypt, GA has been used as a folk medicine for the treatment of periodontal disease and alveolar pyorrhea (treating a bleeding from the gums, removing ulcers in the gums, or promoting a growth of the teeth); lung disorders and liver disorders.
At present, GA is used as an emulsifier with flavour for keeping homogeneity of ingredients of juices and ice-creams, a food additive for maintaining a shape of candies and stabilizers of medicines for compressing tablets or preventing disproportionation of the ingredients in a liquid formulation.
GA is a dietary fiber, which is difficult to digest by digestive enzymes, and is generally known to prevent calcium absorption from the gastrointestinal tract. Tokkyo Kokai H09-67257 (1997) discloses an attempt to give a promoting effect on mineral absorption to chitin by reducing its molecular weight, since chitin with a larger molecular weight, prevents absorption of minerals such as calcium, magnesium and the like. Also a method for improving calcium absorption by adding lactose and sugar-alcohol to dietary fiber is proposed (Tokkyo Kokai 2002-142721).
With respect to GA, an accelerating effect on absorption of water and sodium ion from the small intestine was disclosed, but an accelerating effect of calcium absorption from the small intestine or bone absorption has not been reported.
Dietary fiber is believed to be one of the most important nutrients, since it prevents a rapid increase of blood glucose after a meal by controlling a rate of glucose uptake from the gastrointestinal tract, and avoids constipation with the associated excretion of harmful substances in the intestine.
The present invention provides an accelerating agent of calcium absorption, which can be taken daily, optionally with a dietary fiber, to avoid a calcium deficiency. The inventors have unexpectedly found an accelerating effect of GA on calcium absorption from the gastrointestinal tract.
According to a first aspect of the present invention, an accelerating agent of calcium absorption comprising Gum Arabic is provided.
According to a second aspect of the present invention, there is a calcium-enriched food comprising a calcium agent and the accelerating agent as defined above.
According to a third aspect of the present invention, there is the use of the accelerating agent as defined above, in the manufacture of a calcium-enriched food.
According to a fourth aspect of the present invention, a composition comprises Gum Arabic and a calcium agent, as a combined preparation for simultaneous, separate or sequential use in therapy.
According to a fifth aspect of the present invention, there is the use of Gum Arabic in the manufacture of a medicament for the treatment or prevention of a disease associated with a calcium deficiency.
According to a sixth aspect of the present invention, there is the use of an accelerating agent as defined above, for the manufacture of a medicament for the treatment or prevention of chronic renal failure, or a calcium deficiency associated with chronic renal failure.
According to a seventh aspect of the present invention, there is the use of an accelerating agent as defined above, in the manufacture of a medicament for the treatment or prevention of cardiovascular disorder, including one or more of atherosclerosis, coronary artery disease, ischemic heart disease, hyperlipidemia and hypertension.
According to an eighth aspect of the present invention, there is the use of an accelerating agent as defined above, in the manufacture of a medicament for the treatment or reduction of cholesterol in a hypercholesterolemic subject.
According to a ninth aspect of the present invention, there is the use of an accelerating agent as defined above, in the manufacture of a medicament for the treatment or prevention of malaria.
According to a tenth aspect of the present invention, there is the use of an accelerating agent as defined above, in the manufacture of a medicament for the treatment or prevention of ulcerative colitis.
According to an eleventh aspect of the present invention, there is the use of an accelerating agent as defined above, in the manufacture of a medicament for the treatment or prevention of gingivitis or dental plaque.
According to a twelfth aspect of the present invention, there is the use of an accelerating agent as defined above, in the manufacture of a medicament for the treatment or prevention of learning defects such as Alzheimer's disease or senile dementia.
Calcium deficiency is responsible for brittle bones and may cause osteoporosis and osteomalacia. The present invention makes it possible to improve the efficiency of calcium absorption from the small intestine and/or bone absorption of calcium and to prevent the above diseases, while simultaneously taking dietary fiber which is one of the important nutrients. Therefore, the present invention is also Gum Arabic for the manufacture of a medicament for the treatment or prevention of osteoporosis and/or osteomalacia. The medicament may also include a calcium supplement/agent.
As the water-soluble gum in this invention, a gummy exudation from the stems and/or branch of Acacia species (Leguminosae) such as Acacia Senegal and Acacia seyal may be used in its intact form. From the view point of easy availability and easy formulation, the dried powder of the said gum and/or the extract of the said gum are preferable.
The preferred extraction solvent is water. The aqueous extract can be used as it is, or after concentration, dilution and/or purification.
The dried powder and/or the extract can be purified by means of column chromatography.
The accelerating agent of the present invention can be used by mixing it with a calcium-containing food, for example, a dairy product such as milk, yogurt, cheese and the like, and by adding a calcium agent in a case of calcium-deficient or no calcium-containing food. The calcium agent used in such case includes, but not limited to, a food additive, comprising a calcium salt such as calcium carbonate, calcium lactate, calcium gluconate, calcium acetate, calcium citrate, calcium phosphate, calcium chloride and calcium hydroxide; and natural products such as shell meal, coral powder, egg shell, milk, cow bone powder.
In order to compensate for the lack of calcium, the accelerating agent of the present invention can be used by mixing it with various foods and drinks (calcium-enriched foods) as well as by combining it with a calcium agent described above. The calcium-enriched food includes, is not limited to, carbonated drinks, fruit juice, fermented drinks, milky drinks such as milk; frozen desserts such as ice-cream, ice milk; dairy products such as yogurt, cheese; luncheon meats such as ham, sausage; fish paste products; bread hotcake, prepared dish, cream caramel, soup and the like.
If necessary, an appropriate amount of sweetener such as sugar, honey, glycerine and aspartame, spice such as garlic and ginger, perfume such as fruity flavour, antioxidant such as ethylenediamine disodium salt and sodium thiosulfate, amino acid such as leucine, methionine, lysine, and taurine, and vitamin such as vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, and nicotinamide, can be added to the said drink formulation.
Natural juice such as orange juice, grapefruit juice and vegetable juice (kale, young leaves or barley), and/or the extract of crude drug such as Ginseng and Young Deer Horn also can be added to the said drink formulation for oral administration.
The accelerating agent of the present invention is also available for animals other than humans, and may be used as a pet food such as dog food or cat food, and animal feed.
As described above, the accelerating agent of the present invention may be taken orally by itself or together with other foods or drinks. The amount of the agent to be taken depends on the formulation of each food or drink; and sex, age and body weight of a person taking the agent, but usually 1-100 g/day, preferably 10-50 g/day, and more preferably 10-20 g/day. The agent can be taken in various formulations, after it is dissolved or suspended in cold water, hot water or alcohol.
The effect of GA on calcium absorption from the intestinal tract was assayed according to the following methods.
In each test, purified GA obtained from SANKYO Foods Industry Corp. and calcium L-lactate (Sigma) were used, the latter was known to have high solubility (9600 mg/100 g H2O) and no effect on the taste of food. Male Wistar rats weighing 200-250 g, and about 120 g especially in the experiment of studying calcium born absorption (Test Example 3), were used as an experimental animal.
The abdominal cavity of the rat anesthetized with pentobarbital (50 mg/mL/kg, i.p.) was opened and a silicon tube was inserted into the duodenum and the appendix. A perfusion solution containing calcium (1 mg/mL), or calcium and GA (7.5%) was flowed through the intestinal tract, the perfusing solution was recorded over time, and the calcium content was assayed.
The result is shown in
Usually, calcium concentrations in blood are constantly maintained by biogenic homeostasis and it is difficult to utilize it as an index of calcium absorption. Accordingly, the urinary excretion of calcium was assayed in place of it.
Rats were kept in a metabolic cage and 40 mL of water containing calcium (Ca), Gum Arabic (GA), or Ca and GA (Ca+GA) was given for three days. Furthermore, they were fed a calcium-deficient diet in order to eliminate an effect of calcium contained in the normal diet. After recovering urine, urinary concentration of calcium and urine volume were measured.
The result was shown in
Next, it was studied whether the accelerating effect of GA on calcium absorption reaches bone absorption, and prevents the decease of calcium content in the bone, using rats fed a calcium-deficient diet.
Calcium (Ca-treated group), or calcium and GA ([Ca+GA]-treated group) were orally administered to rats for 30 days with an amount of 1 mg (ca)/day, and changes of hardness and mineral (Ca, Mg, P, Zn) content of the femur, or ALP in blood were observed. Rats were fed a calcium-deficient diet in order to eliminate an effect of calcium contained in the normal diet.
The results were shown in
The [Ca+GA]-treated group showed an increase of the body weight when the body weights 30 days after the administration were compared with that of the start (
Furthermore, contents of various minerals, i.e. Ca, Zn, Mg and P in bone were measured, and the decrease of the Ca, Mg and P contents in bone of the [CA+GA]-treated group was significantly reduced. Alkaline phosphatase (ALP) is an enzyme to accelerate bone absorption of calcium and known to be increased in blood when the contents of calcium in bone is decreased, and also in this experiment the elevation of ALP in blood was observed in the Ca-treated group. However, coadministration of GA showed a tendency to reduce ALP elevation compared with the Ca-treated group.
These experimental results showed that coadministration of Ca and GA improved the efficiency of calcium absorption from the small intestine, and long-term administration reduced the decrease of calcium content in bone. Thus, a novel use of GA for an accelerating agent of bone absorption has been suggested.
The GA (10 g) is dispersed in warm water (40° C., 30 mL) with stirring. After cooling the mixture to 25° C., vitamin B1 (10 mg), vitamin B6 (10 mg), caffeine (50 mg), sugar (5 g), honey (5 g), citric acid (400 mg), sodium citrate (50 mg) and sodium benzoate (35 mg) are added with stirring. The pH value of the resulting mixture is adjusted to 6.0 by addition of lactic acid and/or 0.1N sodium hydroxide. Then the total volume of the resulting solution is adjusted to 5 ml by the addition of water.
GA used in this Example is purified as follows: GA obtained from Acacia Senegal in Sudan is powdered and dissolved in water. Then the resulting solution is filtered and the filtrate is spray-dried to give the said GA.
An accelerating agent of calcium absorption provided by the present invention can be used in a field of calcium-enriched food for example, by mixing with various foods and drinks as well as combining itself with a calcium agent.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2006-041158 | Feb 2006 | JP | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/JP2007/052906 | 2/13/2007 | WO | 00 | 10/6/2008 |
| Number | Date | Country | |
|---|---|---|---|
| 60774374 | Feb 2006 | US |
